SAN DIEGO, March 22 /PRNewswire-FirstCall/ -- Metabasis Therapeutics, Inc. announced today that a poster entitled, “A Phase I/II Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MB07133 in Subjects with Unresectable Hepatocellular Carcinoma (HCC)” will be presented at the 2007 annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, CA. The presentation will take place on April 16, 2007 from 1:00-5:00 p.m. Pacific Time. The poster will provide data on the safety, tolerability, pharmacokinetics and antitumor activity from a dose escalation clinical trial that the Company recently completed in 28 patients with primary liver cancer.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world’s most widespread and costly chronic diseases involving the liver and pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics, Inc.
CONTACT: Constance Bienfait, Vice President, Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575
Web site: http://www.mbasis.com/
